1
|
Bovine adenovirus-3 as a vaccine delivery vehicle. Vaccine 2014; 33:493-9. [PMID: 25498212 PMCID: PMC7115382 DOI: 10.1016/j.vaccine.2014.11.055] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2014] [Revised: 11/21/2014] [Accepted: 11/28/2014] [Indexed: 12/15/2022]
Abstract
The use of vaccines is an effective and relatively inexpensive means of controlling infectious diseases, which cause heavy economic losses to the livestock industry through animal loss, decreased productivity, treatment expenses and decreased carcass quality. However, some vaccines produced by conventional means are imperfect in many respects including virulence, safety and efficacy. Moreover, there are no vaccines for some animal diseases. Although genetic engineering has provided new ways of producing effective vaccines, the cost of production for veterinary use is a critical criterion for selecting the method of production and delivery of vaccines. The cost effective production and intrinsic ability to enter cells has made adenovirus vectors a highly efficient tool for delivery of vaccine antigens. Moreover, adenoviruses induce both humoral and cellular immune responses to expressed vaccine antigens. Since nonhuman adenoviruses are species specific, the development of animal specific adenoviruses as vaccine delivery vectors is being evaluated. This review summarizes the work related to the development of bovine adenovirus-3 as a vaccine delivery vehicle in animals, particularly cattle.
Collapse
|
2
|
Bouet-Cararo C, Contreras V, Caruso A, Top S, Szelechowski M, Bergeron C, Viarouge C, Desprat A, Relmy A, Guibert JM, Dubois E, Thiery R, Bréard E, Bertagnoli S, Richardson J, Foucras G, Meyer G, Schwartz-Cornil I, Zientara S, Klonjkowski B. Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep. PLoS One 2014; 9:e111605. [PMID: 25364822 PMCID: PMC4218782 DOI: 10.1371/journal.pone.0111605] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Accepted: 10/06/2014] [Indexed: 11/29/2022] Open
Abstract
Bluetongue virus (BTV) is an economically important Orbivirus transmitted by biting midges to domestic and wild ruminants. The need for new vaccines has been highlighted by the occurrence of repeated outbreaks caused by different BTV serotypes since 1998. The major group-reactive antigen of BTV, VP7, is conserved in the 26 serotypes described so far, and its role in the induction of protective immunity has been proposed. Viral-based vectors as antigen delivery systems display considerable promise as veterinary vaccine candidates. In this paper we have evaluated the capacity of the BTV-2 serotype VP7 core protein expressed by either a non-replicative canine adenovirus type 2 (Cav-VP7 R0) or a leporipoxvirus (SG33-VP7), to induce immune responses in sheep. Humoral responses were elicited against VP7 in almost all animals that received the recombinant vectors. Both Cav-VP7 R0 and SG33-VP7 stimulated an antigen-specific CD4+ response and Cav-VP7 R0 stimulated substantial proliferation of antigen-specific CD8+ lymphocytes. Encouraged by the results obtained with the Cav-VP7 R0 vaccine vector, immunized animals were challenged with either the homologous BTV-2 or the heterologous BTV-8 serotype and viral burden in plasma was followed by real-time RT-PCR. The immune responses triggered by Cav-VP7 R0 were insufficient to afford protective immunity against BTV infection, despite partial protection obtained against homologous challenge. This work underscores the need to further characterize the role of BTV proteins in cross-protective immunity.
Collapse
Affiliation(s)
| | - Vanessa Contreras
- Virologie et Immunologie Moléculaires, UR 892 INRA, Jouy-en-Josas, France
| | - Agathe Caruso
- INRA, UMR1225, IHAP, Université de Toulouse, INP, ENVT, Toulouse, France
| | - Sokunthea Top
- INRA, UMR1225, IHAP, Université de Toulouse, INP, ENVT, Toulouse, France
| | - Marion Szelechowski
- Centre de Physiopathologie de Toulouse Purpan, INSERM U1043, CNRS U5282, Université Paul-Sabatier, Toulouse, France
| | - Corinne Bergeron
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - Cyril Viarouge
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - Alexandra Desprat
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - Anthony Relmy
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | | | - Eric Dubois
- Unité de pathologie des petits ruminants, ANSES, Sophia-Antipolis, France
| | - Richard Thiery
- Unité de pathologie des petits ruminants, ANSES, Sophia-Antipolis, France
| | - Emmanuel Bréard
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | | | | | - Gilles Foucras
- INRA, UMR1225, IHAP, Université de Toulouse, INP, ENVT, Toulouse, France
| | - Gilles Meyer
- INRA, UMR1225, IHAP, Université de Toulouse, INP, ENVT, Toulouse, France
| | | | - Stephan Zientara
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
| | - Bernard Klonjkowski
- UPE, ANSES, INRA, ENVA, UMR 1161 ANSES/INRA/ENVA, Maisons-Alfort, France
- * E-mail:
| |
Collapse
|